Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing discloses an increase in American Depositary Receipt (ADR) holdings by Mr. E J Gray. The transaction involved the re-investment of a dividend paid to shareholders on October 6, 2011.
- Transaction Date: October 11, 2011
- Price per ADR: $42.37
- Quantity Acquired: 17,058 ADRs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific director transaction described above.
Investor Verification Checklist
- Verify the total ADR holdings of Mr. E J Gray following this transaction.
- Confirm the dividend payment date of October 6, 2011, and the reinvestment terms of the SmithKline Beecham Mid-Term Incentive Plan.
- Check for any other concurrent director transactions not detailed in this specific notification.